tbuckley/cabot-search huggingface dataset:
PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.
Authors: Melissa Amy Lumish, Jenna L. Cohen, Zsofia Kinga Stadler, Jill A Weiss, Michelle F. Lamendola-Essel, Rona Yaeger, Neil Howard Segal, Imane H. El Dika, Leonard B. Saltz, Marina Shcherba, Ryan Sugarman, Avni Mukund Desai, Jesse Joshua Smith, Maria Widmar, Emmanouil Pappou, Philip Paty, Julio Garcia-Aguilar, Martin R. Weiser, Luis A. Diaz, Andrea Cercek
Journal: Journal of Clinical Oncology (2022)

16 Background: Total neoadjuvant therapy with induction chemotherapy and chemoradiation (chemoRT) is the standard treatment for locally advanced rectal adenocarcinomas. Mismatch repair deficient (dMMR) rectal tumors respond poorly to neoadjuvant chemotherapy. PD-1 blockade is effective in patients with metastatic dMMR colorectal cancers, but its efficacy has not been established in the neoadjuvant setting. The purpose of this study is to evaluate the clinical benefit of neoadjuvant PD-1 blockade in dMMR locally advanced rectal cancer. Methods: We designed a prospective, single-arm, phase II study in which patients with stage II and III dMMR rectal cancer receive neoadjuvant dostarlimab (anti-PD-1) for a total of 6 months. The co-primary objectives are to determine the overall response rate (ORR) and pathologic complete response (pCR) or clinical complete response rate (cCR) with or without chemoRT. Tumor assessment with endoscopic evaluation is performed at baseline, 6 weeks, 3 months and 6 months; imaging is performed at pretreatment baseline, 3 months and 6 months. Patients with cCR by previously established criteria are eligible for non-operative management without chemoRT. Those with residual disease after neoadjuvant dostarlimab receive standard chemoRT. Following chemoRT, any patient failing to achieve a cCR is then managed surgically. Results: A total of 13 patients have been enrolled, with median age 52 years (range 26-78), 77% female, and 92% with node-positive disease by rectal MRI. The ORR is 100% in the 12 patients who have undergone at least a 3-month evaluation. Seven patients have completed induction therapy and all 7 (100%) have achieved a cCR and are undergoing observation without chemoRT or surgery. The rate of progressive disease thus far is 0%. No patients have required chemoRT or surgery. There have been no serious adverse events. Conclusions: Single agent neoadjuvant PD-1 blockade with dostarlimab is effective and well-tolerated in locally advanced dMMR rectal adenocarcinoma and allows patients to avoid chemoradiation and surgery. This suggests a potential new paradigm for treatment of dMMR locally advanced rectal cancer. Follow up and further patient accrual is ongoing. Clinical trial information: NCT04165772.
Part III. Basic Information for Use in Studying and Planning State-Cancer-Control Activities, with Organization Charts as of 1945&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1946)

Part III. Basic Information for Use in Studying and Planning State-Cancer-Control Activities, with Organization Charts as of 1945 JNCI: Journal of the National Cancer Institute, Volume 6, Issue 5, April 1946, Pages 249–299, https://doi.org/10.1093/jnci/6.5.249 Published: 01 April 1946
Temporal changes of microvascular obstruction after acute reperfused myocardial infarction Leonarda Galiuto, Antonella Lombardo, Antonio G. Rebuzzi, Luca Santoro, Domenico Cianflone, Filippo Crea, Attilio Maseri. Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
Journal: Journal of the American College of Cardiology (2001)
Managing COVID-19 symptoms (including at the end of life) in the community: summary of NICE guidelines
Journal: BMJ (2020)

### What you need to know Although much focus has been on assessing the severity of COVID-19, general practitioners and other community based clinicians also need a working knowledge of symptom management. Symptoms of cough, fever, and breathlessness can be highly distressing even in those who do not have severe disease. Also, treatments for symptoms in severe COVID-19 will be needed for patients whose advance care plan or advance decision to refuse treatment includes a decision not to escalate treatment beyond home based care. This article summarises key points from the National Institute for Health and Care Excellence (NICE) COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community.1 The guideline is part of a series of rapid guidelines on COVID-19, developed in collaboration with NHS England and NHS Improvement using interim process and methods.2 Recommendations are based on evidence and expert opinion, and have been verified as far as possible by NICE. ### How this guideline summary was prepared This summary is based on the version of the guidance published on 3 April 2020 and has been prepared by The BMJ's clinical editors. Readers should refer to the full guideline on the NICE website for the latest version of the guidance (https://www.nice.org.uk/guidance/ng163) because recommendations will be reviewed and updated by NICE as the knowledge base and expert experience develops. Please see the NICE coronavirus page (https://www.nice.org.uk/covid-19) for additional NICE rapid guidelines on COVID-19. ### Communicating with patients and minimising risk
Abstract 229: Searching Genetic Modifiers For <i>bag3</i> -based Cardiomyopathy Using Adult Zebrafish Models
Authors: Yonghe Ding, Alexey Dvornikov, Xiao Ma, Hong Zhang, Xiaolei Xu
Journal: Circulation Research (2017)

We recently developed a forward mutagenesis screening strategy in adult zebrafish to screen gene-breaking transposon (GBT) mutants, and identified four genetic modifiers for doxorubicin-induced cardiomyopathy. However, it remains unclear whether these genetic modifiers identified from an acquired cardiomyopathy model exert similar modifying effects on inherited cardiomyopathy models. To address this question, we generated BCL2-associated athanogene 3 (bag3) gene knockout in adult zebrafish, using the transcription activator-like effector nucleases (TALEN) genome editing technology. In the bag3-/- fish, progressive cardiac phenotypes reminiscent of human cardiomyopathy such as fetal gene activation, myofibril loss and cardiac dysfunction were detected. At the single myofibril level, reduced active contractility was observed, supporting the dilated cardiomyopathy (DCM)-like phenotype. Based on the ejection fraction index quantified using a newly developed ex vivo assay, different pathogenesis stages including pre-DCM, early-DCM and late DCM were defined. Next, we assessed the potential modifying effects of the four DIC-modifying mutants on bag3 -based cardiomyopathy model. Different from the other three GBT mutants, GBT0411+/- , which tags the long isoform of dnajb6 b gene, dramatically accelerated the cardiac dysfunction and fish mortality in the bag3-/- fish, suggesting dnajb6b as a sensitive genetic modifier for bag3-based cardiomyopathy. Mechanistically, we showed that Bag3 physically interacts with Dnajb6, and we hypothesize that impaired autophagy and/or endoplasmic reticulum stress convey the synergistic cardiac dysfunction and fish mortality phenotypes in the GBT0411+/-;bag3-/- double mutants. In summary, this study demonstrates that an inherited cardiomyopathy model can be established in an adult zebrafish, which can be utilized to search genetic modifiers. Future studies employing this simple vertebrate model amenable to forward mutagenesis screening promise systematic identification of genetic modifiers for different types of cardiomyopathies, a foundation for individualized medicine.
BOOK REVIEWS
Authors: A. E. BOGDEN
Journal: JNCI Journal of the National Cancer Institute (1989)

BOOK REVIEWS Human Tumor Xenografts in Anticancer Drug Development, European School of Oncology Monograph. B. Winograd, M. J. Peckham, H. M. Pinedo, eds. Berlin: Springer-Verlag, 1988, 143 pp. $70.30 ARTHUR E. BOGDEN ARTHUR E. BOGDEN Biomeasure Incorporated11–15 “E”Avenue Hopkinton, MA 01748 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 2, 18 January 1989, Pages 166–167, https://doi.org/10.1093/jnci/81.2.166 Published: 18 January 1989
Does stenting and glycoprotein IIb/IIIa receptor blockade improve the prognosis of diabetics undergoing primary angioplasty in acute myocardial infarction? The CADILLAC trial Thomas Stuckey, Cindy L. Grines, David A. Cox, Eulogio Garcia, James E. Tcheng, John Carroll, Barry Rutherford, Giulio Guagliumi, Paolo Esente, Alexandra J. Lansky, John Griffin, Gregg W. Stone. The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York City, NY, Moses Cone Memorial …
Journal: Journal of the American College of Cardiology (2001)
Error in Affiliations
Authors: Thomas Hank, Marta Sandini, Carlos Fernández-Del Castillo, Carlos Fernández-Del Castillo
Journal: JAMA Surgery (2020)

Francesco Carli, MD, MPhil; Guillaume Bousquet-Dion, MD; Rashami Awasthi, MSc; Noha Elsherbini; Sender Liberman, MD; Marylise Boutros, MD; Barry Stein, MD; Patrick Charlebois, MD; Gabriela Ghitulescu, MD; Nancy Morin, MD; Thomas Jagoe, MD; Celena Scheede-Bergdahl, PhD; Enrico Maria Minnella, MD, PhD; Julio F. Fiore Jr, PhD
Giant genome artwork brightens up London
Authors: A. Ferriman
Journal: BMJ (2001)

Poor antenatal care implicated in half of stillbirths 68, 71Poor antenatal care might have contributed to the outcome in up to half of stillbirths recorded in England, Wales, and Northern Ireland during 1996 and 1997, says a report published last week by the Confidential Enquiry into Stillbirths and Deaths in Infancy.The eighth annual reportpublished as part of the enquiry's ongoing remit to identify areas of suboptimal care contributing to the deaths of babies between 20 weeks' gestation and 1 year of age-showed that stillbirth remained the commonest category of death in this age group.Key areas of concern included lack of coordinated antenatal risk assessment and referral practices throughout pregnancy, poor recognition and management of the growth restricted baby, issues related to fetal movement (failure to act on reduced movements reported by mothers), communication (lack of planning, poor documentation), and lifestyle issues (smoking, poor attendance).
Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention—Reply
Authors: Birgit Vogel, Kurt Huber, Roxana Mehran
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A Pulmonary Embolism Diagnostic Strategy in Patients Hospitalized for COPD Exacerbation
Authors: Wei Xiong, Xuejun Guo
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical records privacy a patient rights issue
Authors: C. Marwick
Journal: JAMA (1996)

A PATIENT has a right to keep personal medical information confidential. The right is paramount and nonnegotiable, says a Boston psychiatrist. Furthermore, ensuring the privacy of health records in employee health plans makes good business sense. Ethically and financially, the bottom lines are similar. Denise M. Nagel, MD, president of the National Coalition for Patient Rights, based in Lexington, Mass, and an instructor in psychiatry at Harvard Medical School, Boston, Mass, gave this advice to human resources managers and others at the 15th National Conference of the Employers' Managed Health Care Association, held in Washington, DC. The group's membership includes some of the nation's largest corporations, such as Xerox, General Motors, and Allied Signal. The members have considerable clout when it comes to negotiating health care plans for their employees. <h3>Privacy Protection Not an Option</h3> "Guarantees that health information is protected are no longer a value-added option," Nagel stated, adding,
Use of open-text responses to recode categorical survey data on postpartum contraception use among women in the United States: A mixed-methods inquiry of Pregnancy Risk Assessment Monitoring System data
Authors: Nicole K. Richards, Christopher P. Morley, Martha A. Wojtowycz, Erin Bevec, Brooke A. Levandowski
Journal: PLoS Medicine (2022)

Postpartum contraception prevents unintended pregnancies and short interpregnancy intervals. The Pregnancy Risk Assessment Monitoring System (PRAMS) collects population-based data on postpartum contraception nonuse and reasons for not using postpartum contraception. In addition to quantitative questions, PRAMS collects open-text responses that are typically left unused by secondary quantitative analyses. However, abundant preexisting open-text data can serve as a resource for improving quantitative measurement accuracy and qualitatively uncovering unexpected responses. We used PRAMS survey questions to explore unprompted reasons for not using postpartum contraception and offer insight into the validity of categorical responses.We used 31,208 categorical 2012 PRAMS survey responses from postpartum women in the US to calculate original prevalences of postpartum contraception use and nonuse and reasons for contraception nonuse. A content analysis of open-text responses systematically recoded data to mitigate survey bias and ensure consistency, resulting in adjusted prevalence calculations and identification of other nonuse themes. Recoded contraception nonuse slightly differed from original reports (21.5% versus 19.4%). Both calculations showed that many respondents reporting nonuse may be at a low risk for pregnancy due to factors like tubal ligation or abstinence. Most frequent nonuse reasons were not wanting to use birth control (27.1%) and side effect concerns (25.0%). Other open-text responses showed common themes of infertility, and breastfeeding as contraception. Comparing quantitative and qualitative responses revealed contradicting information, suggesting respondent misinterpretation and confusion surrounding the term "pregnancy prevention." Though this analysis may be limited by manual coding error and researcher biases, we avoided coding exhaustion via 1-hour coding periods and validated reliability through intercoder kappa scores.In this study, we observed that respondents reporting contraception nonuse often described other methods of pregnancy prevention and contraception barriers that were not included in categorical response options. Open-text responses shed light on a more comprehensive list of pregnancy prevention methods and nonuse options. Our findings contribute to survey questions that can lead to more accurate depiction of postpartum contraceptive behavior. Additionally, future use of these qualitative methods may be used to improve other health behavior survey development and resulting data.
Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo.
Authors: Wyatt Potter, Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Catherine Tempel-Brami, Einav Zeevi, Eyal Dor-On, Rosa S Schneiderman, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Journal: Journal of Clinical Oncology (2022)

464 Background: Hepatocellular carcinoma (HCC) is a highly malignant liver cancer and a leading cause of cancer related mortality. Sorafenib was the first approved systemic treatment for HCC, and remains one of few front-line treatments for this malignancy. Tumor treating fields (TTFields) are low intensity (1-3 V/cm), intermediate frequency (100-500 kHz), alternating electric fields that exert antimitotic effects on cancerous cells. Results of the phase 2 HEPANOVA study of TTFields (150 kHz) plus sorafenib for advanced HCC support investigation of TTFields in a randomized controlled phase 3 study. The current research aimed to describe the in vitro and in vivo efficacy of this combination and to elucidate details regarding the underlying mechanism of action. Methods: In vitro examinations were performed in HepG2 and Huh-7D12 human HCC cell lines, to which TTFields at a frequency of 150 kHz were applied using the inovitro system. Autophagy was examined by western blot and fluorescence detection of microtubule-associated protein light chain 3 (LC3) levels, an accepted autophagy marker. The effect of TTFields in combination with sorafenib was evaluated using cytotoxic, clonogenic, and apoptotic assays. In vivo, SD rats were inoculated orthotopically into the left hepatic lobe with N1S1 HCC cells. 7 days later, TTFields or sham (heat) were applied to the abdominal region of the rats, continuously for 6 days. Daily intraperitoneal injections of sorafenib (10 mg/kg/day) or vehicle were performed during this time. To determine tumor volume growth, MRI images were acquired before and after treatment. Levels of autophagy and apoptosis were examined in tumor sections by immunohistochemistry for LC3 and cleaved PARP, respectively. Results: Application of TTFields induced autophagy in HCC cells. TTFields delivery was cytotoxic to the cells, reduced their colony forming ability, and induced apoptosis while combination with sorafenib elevated these effects. In vivo, tumor volume increased 6-fold in control animals vs 1.6-fold in animals treated with TTFields plus sorafenib. This effect was accompanied by significantly elevated levels of cleaved PARP and LC3 within the tumors of treated relative to control rats. Conclusions: The results demonstrate induction of autophagy and apoptosis in HCC following treatment with TTFields. Concomitant application of TTFields with sorafenib enhanced efficacy via a mechanism that may involve overwhelming autophagy, in vitro and in vivo.
Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Authors: Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett, Julie M Vose, Radhakrishnan Ramchandren, Tatyana A Feldman, Ann S LaCasce, Stephen M Ansell, Craig H. Moskowitz, Keenan Fenton, Carol Anne Ogden, David Taft, Qu Zhang, Kazunobu Kato, Mary Campbell, Ranjana H. Advani
Journal: Blood (2017)
Research in Brief
Authors: Jennifer Thorley
Journal: The Lancet Rheumatology (2020)

Individually calibrated biomechanical footwear therapy could improve pain in people with knee osteoarthritis, according to the single-centre BIOTOK randomised trial by Stephan Reichenbach and colleagues. 220 patients with symptomatic, radiologically confirmed knee osteoarthritis were randomly assigned (1:1) to wear biomechanical footwear with individually adjustable external convex pods attached to the outsole (n=111) or control footwear (n=109) with non-adjustable outsole pods that did not create a convex walking surface.
Concerns About Methods Used in Modeling Study of Risk-Stratified Screening for Breast Cancer
Authors: Nora Pashayan, Paul D. P. Pharoah
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
SERUM DIAGNOSIS APPLIED TO PULMONARY TUBERCULOSIS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Left ventricular outflow tract mean systolic acceleration as a surrogate of the slope of the left ventricular end-systolic pressure-volume relationship Fabrice Bauer, Michael Jones, Takahiro Shiota, Michael Firstenberg, Jian Xin Qin, Hiroyuki Tsujino, Yong Jin Kim, Marta Sitges, Lisa Cardon, Arthur D. Zetts, James D. Thomas. The Cleveland Clinic Foundation, Cleveland, OH, The National Institutes of Health, Bethesda, MD
Journal: Journal of the American College of Cardiology (2001)